Standard Diversified (SDI) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 15, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	SPECIAL DIVERSIFIED OPPORTUNITIES INC.
Entity Central Index Key	911,649
Trading Symbol	sdoi
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		21,035,140
Entity Public Float			$ 15,425,000
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets :
Cash and cash equivalents	$ 23,467	$ 24,818
Other current assets	46	22
Total current assets	23,513	24,840
Total assets	23,513	24,840
Current Liabilities :
Accrued expenses	351	486
Total current liabilities	$ 351	$ 486
COMMITMENTS AND CONTINGENCIES (NOTE 7)
Stockholders' Equity:
Preferred stock, $.01 par value, 20,920,648 shares authorized, no shares issued or outstanding
Common stock, $.01 par value, 50,000,000 shares authorized, and 21,436,767 shares and 21,434,267 shares issued at December 31, 2015 and December 31, 2014, respectively	$ 217	$ 217
Additional paid-in capital	44,172	44,148
Treasury stock, 406,627 common shares at cost at December 31, 2015 and December 31, 2014, respectively	(555)	(555)
Accumulated deficit	(20,672)	(19,456)
Total stockholders' equity	23,162	24,354
Total liabilities and stockholders' equity	$ 23,513	$ 24,840

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,920,648	20,920,648
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	21,436,767	21,434,267
Treasury stock, common shares	406,627	406,627

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Selling, general and administrative	$ 1,216	$ 1,242	$ 1,845
Total operating expenses	1,216	1,242	1,845
Operating loss	(1,216)	(1,242)	(1,845)
Interest income (expense), net		2	(6)
Loss from continuing operations before taxes	$ (1,216)	$ (1,240)	$ (1,851)
Income tax expense (benefit)
Loss from continuing operations, net of taxes	$ (1,216)	$ (1,240)	$ (1,851)
Income from discontinued operations, net of taxes		250	580
Net loss	$ (1,216)	$ (990)	$ (1,271)
Basic and diluted loss per share from continuing operations (in dollars per share)	$ (0.06)	$ (0.06)	$ (0.09)
Basic and diluted income per share from discontinued operations (in dollars per share)		0.01	0.03
Basic and diluted net loss per share (in dollars per share)	$ (0.06)	$ (0.05)	$ (0.06)
Shares used in computing basic and diluted net loss per share (in shares)	21,027,640	21,027,640	20,843,324

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (1,216)	$ (990)	$ (1,271)
Foreign currency translation adjustment			(57)
Reclassification of translation adjustment to discontinued operations			291
Comprehensive loss	$ (1,216)	$ (990)	$ (1,037)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Cumulative Translation Adjustments	Total
Balance at Dec. 31, 2012		$ 215	$ 42,879	$ (555)	$ (17,195)	$ (234)	$ 25,110
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(1,271)		(1,271)
Currency translation adjustment						(57)	(57)
Reclassification of translation adjustment to discontinued operations						$ 291	291
Employee stock purchase plan			9				9
Stock-based compensation			1,466				1,466
Employee purchases of restricted shares		4					4
Shares surrendered in payment of payroll taxes		(2)	(211)				(213)
Balance at Dec. 31, 2013		217	44,143	(555)	(18,466)		25,339
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(990)		(990)
Stock-based compensation			5				5
Balance at Dec. 31, 2014		217	44,148	(555)	(19,456)		24,354
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(1,216)		(1,216)
Stock-based compensation			24				24
Balance at Dec. 31, 2015		$ 217	$ 44,172	$ (555)	$ (20,672)		$ 23,162

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities :
Net loss	$ (1,216)	$ (990)	$ (1,271)
Less: income from discontinued operations		250	580
Loss from continuing operations	(1,216)	(1,240)	(1,851)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities :
Stock-based compensation expense	24	5	28
(Increase) decrease in:
Other current assets	(24)	44	4
Increase (decrease) in :
Accounts payable			(30)
Accrued expenses	(135)	(139)	(1,233)
Net operating activities from discontinued operations		250	256
Net cash used in operating activities	(1,351)	(1,080)	(2,826)
Cash Flows from Investing Activities :
Net proceeds from sale of discontinued operations			10,142
Restricted cash		1,300
Net investing activities from discontinued operations			(569)
Net cash provided by investing activities		1,300	9,573
Cash Flows from Financing Activities :
Proceeds from employee stock purchase plan			9
Proceeds from employee restricted share purchase			4
Purchase of employee restricted shares for withholding taxes			(213)
Net financing activities from discontinued operations			(37)
Net cash used in financing activities			(237)
Effect of exchange rate changes on cash			(57)
Net increase (decrease) in cash and cash equivalents	(1,351)	220	6,453
Cash and Cash Equivalents, Beginning of Year	24,818	24,598	18,145
Cash and Cash Equivalents, End of Year	23,467	24,818	24,598
Supplemental Cash Flow Disclosure :
Noncash investing activity, restricted cash proceeds from sale of discontinued operations			1,300
Noncash investing activity, from discontinued operations			254
Cash paid for taxes, net of tax refunds	$ 27	$ 29	48
Cash paid for interest			$ 15

ASSET SALE

ASSET SALE	12 Months Ended
	Dec. 31, 2015
Asset Sale
ASSET SALE	1. ASSET SALE On April 5, 2013, Special Diversified Opportunities Inc. (f/k/a Strategic Diagnostics Inc.) (“SDOI” or the “Company”), SDIX LLC, a Delaware limited liability company (the “Purchaser”) and OriGene Technologies, Inc., a Delaware corporation and the sole equity holder of the Purchaser (“Parent” or “OriGene”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) pursuant to which the Company agreed, subject to certain terms and conditions including approval of the Company's stockholders, to sell to the Purchaser substantially all of the Company’s rights, title and interest in substantially all of the Company’s non-cash assets related to the Life Sciences Business (the “Asset Sale”). At a special meeting of the stockholders of the Company held on July 10, 2013, the stockholders approved the Asset Sale as contemplated by the Asset Purchase Agreement. On July 12, 2013, the Company completed the Asset Sale. Pursuant to the terms and conditions of the Asset Purchase Agreement, the Purchaser acquired all of the Company’s rights, title, and interest in substantially all of the assets, equipment, inventory, and intellectual property (the “Purchased Assets”) related exclusively to the Company's Life Sciences Business, the product portfolio in respect of which included a full suite of integrated capabilities, including antibody and assay design, development and production and the Company's Advanced Technologies Business. The Purchaser also assumed and agreed to discharge the Assumed Liabilities, as defined in the Asset Purchase Agreement. Parent unconditionally guaranteed Purchaser’s obligations in the Asset Purchase Agreement. The purchase price for the Purchased Assets was $16,000, which was subject to a post-closing working capital adjustment. The Company and Purchaser each made customary representations, warranties and covenants in the Asset Purchase Agreement. At closing, $1,300 of the purchase price was placed in escrow to be governed by the terms of a separate escrow agreement. The Asset Purchase Agreement contained indemnification provisions pursuant to which the Company and the Purchaser agreed to indemnify the other for certain losses, including with respect to environmental, litigation, tax and other matters. The Asset Purchase Agreement also included restrictive covenants, including, that SDOI not (i) engage in a competing business for a period of five years after the closing date, (ii) directly or indirectly solicit Purchaser’s employees for a period of two years after the closing date, (iii) directly or indirectly solicit the Purchaser’s customers for a period of five years after the closing date and (iv) disparage the Purchaser at any time. As a result of the Asset Sale, the Company no longer owns its historical operating assets, and its past business operations have been discontinued. In May 2014, the Company, the Purchaser and OriGene reached a settlement of various claims by the parties relating to the Asset Sale. The terms of the settlement called for the release of the $1,300 in escrow to the Company, as well as the payment by the Purchaser and OriGene of an additional $250 pursuant to the working capital adjustment provisions of the Asset Purchase Agreement.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALALNCE SHEET INFORMATION	12 Months Ended
	Dec. 31, 2015
Accounting Policies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALALNCE SHEET INFORMATION	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALANCE SHEET INFORMATION Business The Company is a shell company as defined in Rule 12b-2 of the Securities Exchange Act of 1934. The Company's board of directors has been exploring strategic alternatives to maximize shareholder value going forward including deploying the proceeds of the Asset Sale in business acquisition opportunities, merging with another company, or other actions to redeploy the Company's capital, including, without limitation, distribution of cash to the Company's shareholders. Prior to the completion of the Asset Sale, the Company was a biotechnology company with a core mission of developing, commercializing and marketing innovative and proprietary products, services and solutions that preserve and enhance the quality of human health and wellness. Basis of Presentation The historical financial statements presented herein include the consolidated financial statements of SDOI and its subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. In addition to the Asset Sale, the Company consummated the sale of its Food Pathogens and AG-GMO products assets in October 2012. The financial information of the Food Pathogens and AG-GMO products as well as the Life Science products have been separately reclassified within the consolidated financial statements as discontinued operations. See Note 3 for further information. The following policies represent the accounting policies followed by the Company prior to the time it became a shell company as a result of the Asset Sale. Foreign Currency Translation The functional currency for the Company’s former United Kingdom branch operation was the British pound. Assets and liabilities related to this foreign operation were translated at the current exchange rates at the end of each period. The resulting translation adjustments are accumulated as a separate component of stockholders’ equity. Revenues and expenses were translated at average exchange rates in effect during the period with foreign currency transaction gains and losses, if any, included in results of operations. As a result of the Asset Sale, the translation adjustment as of the closing date was reclassified to discontinued operations. Use of Estimates The preparation of the consolidated financial statements requires the management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the period. These estimates include those made in connection with deferred tax assets. Actual results could differ from those estimates. Cash and cash equivalents The Company considers all highly liquid investments that have maturities of three months of less when acquired to be cash equivalents. As of December 31, 2015 and 2014, cash of $23,467 and $24,818, respectively, consisted of bank checking operating accounts. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method, which requires that compensation costs related to employee share-based payment transactions are measured in the financial statements at fair value on the date of grant and are recognized over the vesting period of the award. Research and Development Prior to the completion of the Asset Sale, research and development costs were charged to expense as incurred. Accounting for Income Taxes Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such changes are enacted. The Company utilizes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result of the implementation of authoritative guidance related to the accounting for uncertainty in income taxes, the Company recognizes in its financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The authoritative guidance also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company includes interest and penalties related to unrecognized tax benefits as a component of income tax expense. See Note 9 for further information. Basic and Diluted Loss per Share Basic loss per share (EPS) is computed by dividing net loss available for common stockholders by the weighted-average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS, except that the dilutive effect of converting or exercising all potentially dilutive securities is also included in the denominator. The Company’s calculation of diluted EPS includes the dilutive effect of exercising stock options into common shares and the inclusion of unvested restricted stock awards. Basic loss per share excludes potentially dilutive securities. For the years 2015, 2014 and 2013, conversion of stock options with exercise prices less than the market share price and unvested restricted shares totaling 7,500, 0, and 0, respectively, into common share equivalents were excluded from this calculation because they were anti-dilutive, due to the net losses recorded in the periods. For the years 2015, 2014 and 2013, certain other stock options were excluded from common share equivalents as all had exercise prices greater than the market share price at December 31, 2015, 2014 and 2013, respectively. Listed below are the basic and diluted share calculations for the years ended December 31, 2015, 2014 and 2013: 2015 2014 2013 Weighted average common shares outstanding 21,027,640 21,027,640 20,843,324 Shares used in computing basic and diluted net loss per share 21,027,640 21,027,640 20,843,324 Treasury Stock Shares of common stock repurchased by the Company are recorded at cost as treasury stock in the stockholders’ equity section of the consolidated balance sheet, and as a use of cash in the financing activities section of the consolidated statement of cash flows. Comprehensive Loss Comprehensive loss is comprised of net loss and currency translation adjustments and is presented in the consolidated statements of comprehensive loss. Statements of Cash Flows The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	12 Months Ended
	Dec. 31, 2015
Discontinued Operations
DISCONTINUED OPERATIONS	3. DISCONTINUED OPERATIONS On October 16, 2012, the Company completed the sale of its Food Pathogens and AG-GMO products assets to Romer Labs for approximately $12,075, net of transaction fees. These assets included intellectual property, inventory, commercial contracts and equipment. The Company recognized a gain on the sale of these assets, after transaction fees, of $9,882. The Company had the opportunity to receive additional consideration of up to $600 if it was able to meet certain conditions as provided for in the agreement with Romer Labs. As of December 31, 2013, the Company received $300 pursuant to this additional consideration, all of which is recorded as a gain on sale of assets in the Company’s financial results for the year ended December 31, 2013. The Company will not receive the remaining $300 related to this additional consideration. On July 12, 2013, the Company completed the sale of its Life Sciences products assets to SDIX LLC for approximately $16,000 before transaction fees. These assets included intellectual property, inventory, commercial contracts and equipment. The Company recognized a gain on the sale of these assets, after transaction fees, of $2,345. For presentation purposes, $125 of the costs related to the acquisition were previously expensed in the fourth quarter of 2012, respectively, as general and administrative costs. The Company has reclassified these expenses to discontinued operations. At the closing of the Asset Sale, $1,300 of the purchase price was placed in escrow to satisfy any indemnification claims that were brought by April 12, 2014. In addition, the Asset Purchase Agreement provided for an adjustment to the purchase price based upon the actual working capital, as defined, on the closing date as compared to a working capital target amount. In May 2014, the Company, the Purchaser and OriGene reached a settlement of various claims by the parties relating to the Asset Sale. The terms of the settlement called for the release of the $1,300 in escrow to the Company, as well as the payment by the Purchaser and OriGene to the Company of an additional $250 pursuant to the working capital adjustment provisions of the Asset Purchase Agreement. The settlement also included mutual releases of these and all other claims under the Asset Purchase Agreement. The results of operations and cash flow activity of the Food Pathogens, AG-GMO and Life Science products have been reclassified separately as discontinued operations within the consolidated financial statements for all periods presented. The following table presents key information associated with the operating results of the discontinued operations for the reporting periods included in the Company’s 2014 and 2013 consolidated statements of operations: Results of Operations of Discontinued Operations Year Ended December 31, 2014 2013 Revenues $ - $ 7,564 Cost of sales - 4,417 Gross profit - 3,147 Operating expenses: Research and development - 960 Selling, general and administrative - 4,355 Gain on sale of assets (250 ) (2,770 ) Total operating expenses (250 ) 2,545 Operating income 250 602 Interest expense - (8 ) Income before income taxes 250 594 Income tax expense - 14 Income from discontinued operations $ 250 $ 580

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT The Company's property, plant and equipment was sold as part of the Asset Sale. Depreciation expense included in discontinued operations was $563 in 2013.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Accrued Expenses
ACCRUED EXPENSES	5. ACCRUED EXPENSES As of December 31, accrued expenses consisted of the following: 2015 2014 Compensation $ 72 $ 112 Professional fees 83 122 Other 196 252 Total accrued expenses $ 351 $ 486

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2015
Share-Based Compensation
SHARE-BASED COMPENSATION	6. SHARE-BASED COMPENSATION Under various plans, executives, key employees and outside directors receive awards of options to purchase common stock. The Company has a stock option plan (the “2000 Plan”) which authorizes the granting of incentive and nonqualified stock options and restricted stock awards. Incentive stock options are granted at not less than 100% of fair market value at the date of grant (110% for stockholders owning more than 10% of the Company’s common stock). Nonqualified stock options are granted at not less than 85% of fair market value at the date of grant. A maximum of 8,000,000 shares of common stock are issuable under the 2000 Plan. Certain additional options have been granted outside the 2000 Plan. These options generally follow the provisions of the 2000 Plan. The Company issues new shares to satisfy option exercises and the vesting of restricted stock awards. The Company also has an Employee Stock Purchase Plan (the “ESPP”). The ESPP allows eligible full-time employees to purchase shares of common stock at 90 percent of the lower of the fair market value of a share of common stock on the first or last day of the quarter. Eligible employees are provided the opportunity to acquire Company common stock during each quarter. No more than 661,157 shares of common stock may be issued under the ESPP. Such stock may be unissued shares or treasury shares of the Company or may be outstanding shares purchased in the open market or otherwise on behalf of the ESPP. For financial reporting purposes, the Company’s ESPP is compensatory. Therefore, the Company is required to recognize compensation expense related to the discount from market value of shares sold under the ESPP. The Company issues new shares to satisfy shares purchased under the ESPP. Share-based compensation expense recorded in 2015, 2014 and 2013 is summarized as follows: 2015 2014 2013 Stock options $ 13 $ 5 $ 611 Employee stock purchase plan - - 1 Restricted stock awards and restricted stock units 11 - 854 Total share-based compensation expense $ 24 $ 5 $ 1,466 The deferred income tax benefit related to share-based compensation expense for the years ended December 31, 2015, 2014 and 2013 was $0 due to the full valuation allowance recorded against deferred tax assets (see Note 9). Share-based compensation expense of $24, $5 and $28 in 2015, 2014 and 2013, respectively, is a component of selling, general and administrative expense, and is recorded as a non-cash expense in the operating activities section of the consolidated statement of cash flows. All other share-based compensation is included in discontinued operations. As a result of the Asset Sale, all then outstanding unvested stock options, unvested restricted shares and unvested performance based restricted stock units vested on July 12, 2013. The expense of approximately $1,169 related to this acceleration of vesting was recorded in the Company's fiscal third quarter, with approximately $431 related to stock options and $738 related to restricted stock awards. Information with respect to the stock options granted under the 2000 Plan and options granted separately from the 2000 Plan is summarized as follows: Weighted Aggregate Number Average Remaining Instrinsic of Shares Price Range Contractual term Value Balance, January 1, 2013 2,170,043 $ 1.49 - $ 4.65 Granted 556,200 $ 1.19 - $ 1.50 Cancelled / forfeited (1,246,749 ) $ 1.19 - $ 4.65 Balance, December 31, 2013 1,479,494 $ 1.25 - $ 4.60 Granted 23,076 $ 1.30 - $ 1.30 Cancelled / forfeited (528,000 ) $ 1.50 - $ 4.60 Balance, December 31, 2014 974,570 $ 1.25 - $ 3.74 Granted 60,000 $ 1.24 - $ 1.24 Cancelled / forfeited (350,000 ) $ 1.25 - $ 1.50 Balance, December 31, 2015 684,570 $ 1.24 - $ 3.74 4.2 years $ - Vested and exercisable at December 31, 2015 654,570 $ 1.24 - $ 3.74 4.1 years $ - As of December 31, 2015, options covering 654,570 shares were exercisable with a weighted average exercise price of $1.80 per share, and 3,921,011 shares were available for future grant under the 2000 Plan. As of December 31, 2015, unrecognized compensation expense related to outstanding non-performance based stock options was $5. The weighted average fair value at the date of grant for non-performance based options granted during 2015, 2014 and 2013 was estimated at $0.23, $0.40 and $0.31 per share, respectively, using the Black-Scholes pricing model. The weighted-average assumptions used in the Black-Scholes model were as follows: dividend yield of 0%, expected volatility of 26% in 2015, 38% in 2014 and 38% in 2013, risk-free interest rate of 1.71% in 2015, 1.71% in 2014 and 1.05% in 2013 and expected option life of 4.25 years in 2015, 5.5 years in 2014 and 5 years in 2013. The expected option life was computed using the sum of the average vesting period and the contractual life of the option and dividing by 2, for all periods presented. The Company issued options to acquire 350,000 shares of common stock with performance based vesting during the year ended December 31, 2013. These options were cancelled in 2015. The following table provides additional information about the Company’s stock options outstanding at December 31, 2015: Options Outstanding Options Exercisable Weighted Average Wtd. Average Range of Number of Remaining Exercise Number of Exercise Exercise Prices Shares Contractual Life Price Shares Price $ 1.24 - $ 1.85 477,528 4.1 Years $ 1.51 447,528 $ 1.53 $ 2.00 - $ 2.25 175,000 4.8 Years $ 2.13 175,000 $ 2.13 $ 3.69 - $ 3.74 32,042 2.3 Years $ 3.72 32,042 $ 3.72 $ 1.24 - $ 3.74 684,570 4.2 Years $ 1.77 654,570 $ 1.80 The Company grants restricted stock awards (RSA) which is the right to receive shares. The fair value of RSAs is based on the market price for the stock at the date of grant. RSAs generally vest over periods of two to five years. The following table summarizes the changes in non-vested restricted stock units for the three year period ended December 31, 2015: Weighted Average Grant Date Aggregate Shares Fair Value Intrinsic Value Non-vested RSAs at January 1, 2013 445,000 $ 1.60 Granted 225,000 $ 1.58 Vested (620,000 ) $ 1.60 Cancelled / forfeited (50,000 ) $ 1.59 Non-vested RSAs at December 31, 2013 - $ 0.00 Granted - $ 0.00 Vested - $ 0.00 Cancelled / forfeited - $ 0.00 Non-vested RSAs at December 31, 2014 - $ 0.00 Granted 15,000 $ 1.13 Vested (7,500 ) $ 1.13 Cancelled / forfeited - Non-vested RSAs at December 31, 2015 7,500 $ 1.13 Of the 7,500 RSA’s that vested in 2015, 2,500 common shares were issued in December 2015 and are included in the number of common shares outstanding at December 31, 2015. Common shares for the remaining 5,000 vested RSA’s were issued in January 2016. The Company recorded compensation expense of $11, $0 and $854, respectively, for the years ended December 31, 2015, 2014 and 2013, for RSAs. The expense in 2013 is included in discontinued operations. As of December 31, 2015, there is unrecognized compensation expense of $6 related to RSAs. The Company also issued 410,000 performance-based Restricted Stock Units (“RSUs”) during the year ended December 31, 2012, of which 200,000 have been forfeited. The fair value of an RSU is equal to the market value of a share of stock on the date of grant. The performance-based RSUs vest based upon the achievement of certain goals related to the Company’s senior management team, for periods ranging from June 30, 2012 through December 31, 2015. Unless forfeited, the performance-based RSUs will be paid out in the form of stock, if the Company meets the performance targets. If the designated performance targets are not met, no payout will be made. The performance conditions related to 210,000 RSUs were met in 2013, and these shares are included in the Restricted Stock summary above.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies.
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES The Company leases its office facilities under operating leases. Rent expense in continuing operations for each of the years ended December 31, 2015, 2014 and 2013, was $28. There are no future commitments under non-cancelable leases at December 31, 2015. The Company’s subsidiary, AZUR Environmental Limited, is the lessee for a real property lease located in the United Kingdom. In 2001, the landlord of the property gave AZUR Environmental Limited its consent to allow AZUR to assign the lease and its related obligations to a third party. As inducement to the landlord to grant the assignment, AZUR was required to guarantee performance under the original lease terms if the third party fails to perform. The Company believes that based on its assessment of the current financial strength of the third party, no liability is required to be recorded with regard to the guarantee or lease obligation. The lease term expires in November 2016 and provides for annual principal rent payments of approximately $150 per year in the aggregate. The Company is subject to various claims arising in the ordinary course of business. Although the ultimate outcome of these matters is presently not determinable, management does not believe that the outcome of these matters will have a material adverse effect on the Company’s financial position or results of operations.

RETIREMENT SAVINGS PLAN

RETIREMENT SAVINGS PLAN	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement
RETIREMENT SAVINGS PLAN	8. RETIREMENT SAVINGS PLAN The Company maintained a retirement savings plan qualified under Section 401(k) of the Internal Revenue Code. The plan allowed for eligible employees to contribute a portion of their gross wages to the plan. The Company matched employees’ contributions on a 100% basis up to 1% of gross wages and on a 50% basis up to the next 5% of gross wages. All employee and Company matching contributions ceased upon the closing of the Asset Sale and the Company has terminated the plan. All plan balances were distributed as of December 31, 2013. In 2013, the Company recognized expense of $124 associated with this plan. This expense is included in discontinued operations.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax
INCOME TAXES	9. INCOME TAXES The components of income (loss) from continuing operations before tax expense as of December 31 are as follows: 2015 2014 2013 United States $ (1,216 ) $ (1,240 ) $ (1,851 ) Rest of the world - - - Total $ (1,216 ) $ (1,240 ) $ (1,851 ) No income tax expense (benefit) is attributable to continuing operations as of December 31, 2015, 2014 or 2013. The following table summarizes the significant differences between the U.S. Federal statutory rate and the Company’s effective tax rate for financial statement purposes on income from continuing operations: 2015 2014 2013 % % % Statutory tax rate 34.0 34.0 34.0 Valuation allowance, federal (34.0 ) (27.1 ) 20.9 Valuation allowance related to discontinued operations - (6.9 ) (10.1 ) Stock compensation expense - - (34.8 ) Subpart F income - - (9.8 ) Other, net - - (0.2 ) Total 0.0 % 0.0 % 0.0 % Significant components of the Company’s deferred tax assets as of December 31 are as follows: 2015 2014 Net operating loss carryforwards $ 8,281 $ 7,513 Credit carryforwards 1,297 1,310 Non-deductible reserves 326 574 Total deferred tax assets 9,904 9,397 Valuation allowance (9,904 ) (9,397 ) Net deferred tax assets $ - $ - For the year ended December 31, 2015, the Company recorded no income tax expense. Overall, the valuation allowance for deferred tax assets increased during 2015 by $507. The valuation allowance increased by $412 related to the current year net operating loss and $95 related to the current year increase in deferred tax assets. FASB ASC 740, Accounting for Income Taxes At December 31, 2015, the Company had U.S. federal net operating loss carryforwards of approximately $20,098 including those of acquired companies, which will expire as follows: Year Net Operating Loss (in 2022 $ 1,674 2024 1,876 2025 3 2026 1 2027 1 2028 3,492 2029 2,501 2030 1,281 2031 391 2033 6,625 2034 452 2035 1,801 Total $ 20,098 The above includes net operating losses of $668 which, if realized, would be accounted for as additional paid in capital and excludes $1,257 related to unrecognized tax benefits. The Company has federal research and experimentation credit carryforwards of $1,068, net of $119 related to unrecognized tax benefits, as of December 31, 2015, which are set to expire in years 2020 through 2032. The Company also has federal alternative minimum tax credit carryforwards of $10 which have indefinite lives. For the year ended December 31, 2015, the Company had no change in its unrecognized tax benefits. The following table is a reconciliation of the gross unrecognized tax benefits during the years ended December 31: 2015 2014 2013 Gross unrecognized tax benefits as of January 1 $ 628 $ 619 $ 590 Increases from positions taken in prior periods - - 2 Increases from positions taken in current period - 9 27 Gross unrecognized tax benefits as of December 31 $ 628 $ 628 $ 619 The unrecognized tax benefits at December 31, 2015 of $628, if recognized in a period where there was not a full valuation allowance, would affect the effective tax rate. The Company is subject to U.S. federal income tax, as well as income taxes of multiple state jurisdictions. The Company recognizes accrued interest expense and penalties related to uncertain tax benefits that have resulted in a refund or reduction of income taxes paid. Unrecognized tax benefits aggregating $622 would reduce already existing net operating loss and tax credit carryforwards and therefore require no accrual for interest or penalty in any of the years 2015, 2014 or 2013. The remaining unrecognized tax benefit of $6 include de minimis interest and penalty where required. For federal purposes, post-1997 tax years remain open to examination as a result of net operating loss carryforwards. For state purposes, the statute of limitations remains open in a similar manner for states that have generated net operating losses. The Company does not expect that the total amount of unrecognized tax benefits related to positions taken in prior periods will change significantly during the next twelve months.

QUARTERLY FINANCIAL DATA (unaud

QUARTERLY FINANCIAL DATA (unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information
QUARTERLY FINANCIAL DATA (unaudited)	10. QUARTERLY FINANCIAL DATA (unaudited) Three Months Ended, March 31 June 30 September 30 December 31 (In thousands except per share data) 2015 Loss from continuing operations $ (251 ) $ (291 ) $ (268 ) $ (406 ) Income from discontinued operations - - - - Net income (loss) (251 ) (291 ) (268 ) (406 ) Basic and diluted loss per share from continuing operations (0.01 ) (0.01 ) (0.01 ) (0.02 ) Basic and diluted income per share from discontinued operations - - - - Basic and diluted net loss per share (0.01 ) (0.01 ) (0.01 ) (0.02 ) 2014 Loss from continuing operations $ (340 ) $ (343 ) $ (261 ) $ (296 ) Income (loss) from discontinued operations 0 250 - 0 Net income (loss) (340 ) (93 ) (261 ) (296 ) Basic and diluted loss per share from continuing operations (0.02 ) (0.02 ) (0.01 ) (0.02 ) Basic and diluted income per share from discontinued operations - 0.01 - - Basic and diluted net income (loss) per share (0.02 ) - (0.01 ) (0.02 )

SUBSEQUENT EVENT

SUBSEQUENT EVENT	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENT	11. SUBSEQUENT EVENT On February 29, 2016, the Company was informed by B. Riley & Co., LLC ("B. Riley") that it had sold 3,504,172 shares of the Company's common stock in a transaction that is matchable against B. Riley's purchase of 742,344 shares of the Company's common stock in December 2015. In accordance with Section 16(b) of the Securities Exchange Act of 1934 which provides that any profit realized by an insider on short-swing transactions must be disgorged to the Company, B. Riley paid the Company $133 for the disgorgement of profits in connection with these matchable transactions. This amount will be credited to additional paid-in capital during the quarter ending March 31, 2016.

SUMMARY OF SIGNIFICANT ACCOUN19

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALANCE SHEET INFORMATION (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies
Business	Business The Company is a shell company as defined in Rule 12b-2 of the Securities Exchange Act of 1934. The Company's board of directors has been exploring strategic alternatives to maximize shareholder value going forward including deploying the proceeds of the Asset Sale in business acquisition opportunities, merging with another company, or other actions to redeploy the Company's capital, including, without limitation, distribution of cash to the Company's shareholders. Prior to the completion of the Asset Sale, the Company was a biotechnology company with a core mission of developing, commercializing and marketing innovative and proprietary products, services and solutions that preserve and enhance the quality of human health and wellness.
Basis of Presentation	Basis of Presentation The historical financial statements presented herein include the consolidated financial statements of SDOI and its subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. In addition to the Asset Sale, the Company consummated the sale of its Food Pathogens and AG-GMO products assets in October 2012. The financial information of the Food Pathogens and AG-GMO products as well as the Life Science products have been separately reclassified within the consolidated financial statements as discontinued operations. See Note 3 for further information. The following policies represent the accounting policies followed by the Company prior to the time it became a shell company as a result of the Asset Sale.
Foreign Currency Translation	Foreign Currency Translation The functional currency for the Company’s former United Kingdom branch operation was the British pound. Assets and liabilities related to this foreign operation were translated at the current exchange rates at the end of each period. The resulting translation adjustments are accumulated as a separate component of stockholders’ equity. Revenues and expenses were translated at average exchange rates in effect during the period with foreign currency transaction gains and losses, if any, included in results of operations. As a result of the Asset Sale, the translation adjustment as of the closing date was reclassified to discontinued operations.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements requires the management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the period. These estimates include those made in connection with deferred tax assets. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments that have maturities of three months of less when acquired to be cash equivalents. As of December 31, 2015 and 2014, cash of $23,467 and $24,818, respectively, consisted of bank checking operating accounts.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method, which requires that compensation costs related to employee share-based payment transactions are measured in the financial statements at fair value on the date of grant and are recognized over the vesting period of the award.
Research and Development	Research and Development Prior to the completion of the Asset Sale, research and development costs were charged to expense as incurred.
Accounting for Income Taxes	Accounting for Income Taxes Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such changes are enacted. The Company utilizes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result of the implementation of authoritative guidance related to the accounting for uncertainty in income taxes, the Company recognizes in its financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The authoritative guidance also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company includes interest and penalties related to unrecognized tax benefits as a component of income tax expense. See Note 9 for further information.
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share Basic loss per share (EPS) is computed by dividing net loss available for common stockholders by the weighted-average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS, except that the dilutive effect of converting or exercising all potentially dilutive securities is also included in the denominator. The Company’s calculation of diluted EPS includes the dilutive effect of exercising stock options into common shares and the inclusion of unvested restricted stock awards. Basic loss per share excludes potentially dilutive securities. For the years 2015, 2014 and 2013, conversion of stock options with exercise prices less than the market share price and unvested restricted shares totaling 7,500, 0, and 0, respectively, into common share equivalents were excluded from this calculation because they were anti-dilutive, due to the net losses recorded in the periods. For the years 2015, 2014 and 2013, certain other stock options were excluded from common share equivalents as all had exercise prices greater than the market share price at December 31, 2015, 2014 and 2013, respectively. Listed below are the basic and diluted share calculations for the years ended December 31, 2015, 2014 and 2013: 2015 2014 2013 Weighted average common shares outstanding 21,027,640 21,027,640 20,843,324 Shares used in computing basic and diluted net loss per share 21,027,640 21,027,640 20,843,324
Treasury Stock	Treasury Stock Shares of common stock repurchased by the Company are recorded at cost as treasury stock in the stockholders’ equity section of the consolidated balance sheet, and as a use of cash in the financing activities section of the consolidated statement of cash flows.
Comprehensive Income (Loss)	Comprehensive Loss Comprehensive loss is comprised of net loss and currency translation adjustments and is presented in the consolidated statements of comprehensive loss.
Statements of Cash Flows	Statements of Cash Flows The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

SUMMARY OF SIGNIFICANT ACCOUN20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALANCE SHEET INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies
Weighted Average Number of Shares	2015 2014 2013 Weighted average common shares outstanding 21,027,640 21,027,640 20,843,324 Shares used in computing basic and diluted net loss per share 21,027,640 21,027,640 20,843,324

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations
Operating Results of Discontinued Operation	Year Ended December 31, 2014 2013 Revenues $ - $ 7,564 Cost of sales - 4,417 Gross profit - 3,147 Operating expenses: Research and development - 960 Selling, general and administrative - 4,355 Gain on sale of assets (250 ) (2,770 ) Total operating expenses (250 ) 2,545 Operating income 250 602 Interest expense - (8 ) Income before income taxes 250 594 Income tax expense - 14 Income from discontinued operations $ 250 $ 580

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Accrued Expenses	2015 2014 Compensation $ 72 $ 112 Professional fees 83 122 Other 196 252 Total accrued expenses $ 351 $ 486

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2015
Share-Based Compensation
Share Based Compensation Expense	2015 2014 2013 Stock options $ 13 $ 5 $ 611 Employee stock purchase plan - - 1 Restricted stock awards and restricted stock units 11 - 854 Total share-based compensation expense $ 24 $ 5 $ 1,466
Activity of Outstanding Stock Options Granted	Weighted Aggregate Number Average Remaining Instrinsic of Shares Price Range Contractual term Value Balance, January 1, 2013 2,170,043 $ 1.49 - $ 4.65 Granted 556,200 $ 1.19 - $ 1.50 Cancelled / forfeited (1,246,749 ) $ 1.19 - $ 4.65 Balance, December 31, 2013 1,479,494 $ 1.25 - $ 4.60 Granted 23,076 $ 1.30 - $ 1.30 Cancelled / forfeited (528,000 ) $ 1.50 - $ 4.60 Balance, December 31, 2014 974,570 $ 1.25 - $ 3.74 Granted 60,000 $ 1.24 - $ 1.24 Cancelled / forfeited (350,000 ) $ 1.25 - $ 1.50 Balance, December 31, 2015 684,570 $ 1.24 - $ 3.74 4.2 years $ - Vested and exercisable at December 31, 2015 654,570 $ 1.24 - $ 3.74 4.1 years $ -
Additional Information About Stock Options Outstanding and Exercisable	Options Outstanding Options Exercisable Weighted Average Wtd. Average Range of Number of Remaining Exercise Number of Exercise Exercise Prices Shares Contractual Life Price Shares Price $ 1.24 - $ 1.85 477,528 4.1 Years $ 1.51 447,528 $ 1.53 $ 2.00 - $ 2.25 175,000 4.8 Years $ 2.13 175,000 $ 2.13 $ 3.69 - $ 3.74 32,042 2.3 Years $ 3.72 32,042 $ 3.72 $ 1.24 - $ 3.74 684,570 4.2 Years $ 1.77 654,570 $ 1.80
Status of Unvested Restricted Stock Activity	Weighted Average Grant Date Aggregate Shares Fair Value Intrinsic Value Non-vested RSAs at January 1, 2013 445,000 $ 1.60 Granted 225,000 $ 1.58 Vested (620,000 ) $ 1.60 Cancelled / forfeited (50,000 ) $ 1.59 Non-vested RSAs at December 31, 2013 - $ 0.00 Granted - $ 0.00 Vested - $ 0.00 Cancelled / forfeited - $ 0.00 Non-vested RSAs at December 31, 2014 - $ 0.00 Granted 15,000 $ 1.13 Vested (7,500 ) $ 1.13 Cancelled / forfeited - Non-vested RSAs at December 31, 2015 7,500 $ 1.13

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax
Components of Loss from Continuing Operations before Tax Expense	2015 2014 2013 United States $ (1,216 ) $ (1,240 ) $ (1,851 ) Rest of the world - - - Total $ (1,216 ) $ (1,240 ) $ (1,851 )
Significant Differences between Federal Statutory Rate and Company Effective Tax Rate on Income from Continuing Operations	2015 2014 2013 % % % Statutory tax rate 34.0 34.0 34.0 Valuation allowance, federal (34.0 ) (27.1 ) 20.9 Valuation allowance related to discontinued operations - (6.9 ) (10.1 ) Stock compensation expense - - (34.8 ) Subpart F income - - (9.8 ) Other, net - - (0.2 ) Total 0.0 % 0.0 % 0.0 %
Significant Components of Deferred Tax Assets	2015 2014 Net operating loss carryforwards $ 8,281 $ 7,513 Credit carryforwards 1,297 1,310 Non-deductible reserves 326 574 Total deferred tax assets 9,904 9,397 Valuation allowance (9,904 ) (9,397 ) Net deferred tax assets $ - $ -
United States Federal Net Operating Loss Carryforwards	Year Net Operating Loss (in 2022 $ 1,674 2024 1,876 2025 3 2026 1 2027 1 2028 3,492 2029 2,501 2030 1,281 2031 391 2033 6,625 2034 452 2035 1,801 Total $ 20,098
Reconciliation of gross Unrecognized Tax Benefits	2015 2014 2013 Gross unrecognized tax benefits as of January 1 $ 628 $ 619 $ 590 Increases from positions taken in prior periods - - 2 Increases from positions taken in current period - 9 27 Gross unrecognized tax benefits as of December 31 $ 628 $ 628 $ 619

QUARTERLY FINANCIAL DATA (una25

QUARTERLY FINANCIAL DATA (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information
Quarterly Financial Data	Three Months Ended, March 31 June 30 September 30 December 31 (In thousands except per share data) 2015 Loss from continuing operations $ (251 ) $ (291 ) $ (268 ) $ (406 ) Income from discontinued operations - - - - Net income (loss) (251 ) (291 ) (268 ) (406 ) Basic and diluted loss per share from continuing operations (0.01 ) (0.01 ) (0.01 ) (0.02 ) Basic and diluted income per share from discontinued operations - - - - Basic and diluted net loss per share (0.01 ) (0.01 ) (0.01 ) (0.02 ) 2014 Loss from continuing operations $ (340 ) $ (343 ) $ (261 ) $ (296 ) Income (loss) from discontinued operations 0 250 - 0 Net income (loss) (340 ) (93 ) (261 ) (296 ) Basic and diluted loss per share from continuing operations (0.02 ) (0.02 ) (0.01 ) (0.02 ) Basic and diluted income per share from discontinued operations - 0.01 - - Basic and diluted net income (loss) per share (0.02 ) - (0.01 ) (0.02 )

ASSET SALE (Detail Textuals)

ASSET SALE (Detail Textuals) - USD ($) $ in Thousands	Jul. 12, 2013	May. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price placed in escrow		$ 1,300
Working capital adjustment provisions		$ 250
Divestiture | Life Science
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of a business	$ 16,000
Asset Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price placed in escrow	$ 1,300
Period of restriction for engaging in competing business	5 years
Period of restriction for soliciting purchaser's employees	2 years
Period of restriction for soliciting purchaser's customers	5 years
Working capital adjustment provisions	$ 250

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALANCE SHEET INFORMATION (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Weighted average common shares outstanding	21,027,640	21,027,640	20,843,324
Shares used in computing basic and diluted net loss per share (in shares)	21,027,640	21,027,640	20,843,324

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND CERTAIN BALALNCE SHEET INFORMATION (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]
Cash and cash equivalents	$ 23,467	$ 24,818	$ 24,598	$ 18,145
Conversion of stock options and unvested restricted shares excluded from computation of earnings per share	7,500	0	0

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations
Revenues			$ 7,564
Cost of sales			4,417
Gross profit			3,147
Operating expenses:
Research and development			960
Selling, general and administrative			4,355
Gain on sale of assets		$ (250)	(2,770)
Total operating expenses		(250)	2,545
Operating income		$ 250	602
Interest expense			(8)
Income before income taxes		$ 250	594
Income tax expense			14
Income from discontinued operations	$ 250	$ 250	$ 580

DISCONTINUED OPERATIONS (Deta30

DISCONTINUED OPERATIONS (Detail Textuals) - USD ($) $ in Thousands	Jul. 12, 2013	Oct. 16, 2012	May. 31, 2014	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets, net of transaction fees						$ 10,142
Gain on sale of assets, net of transaction fees					$ 250	2,770
Purchase price released from escrow			$ 1,300
Working capital adjustment provisions			$ 250
Asset Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Additional consideration not receivable						300
Purchase price released from escrow	$ 1,300
Working capital adjustment provisions	250
Life Science
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets, net of transaction fees	16,000
Gain on sale of assets, net of transaction fees	$ 2,345
Costs related to the acquisition, previously expensed, to be reclassified to discontinued operations				$ 125
Food pathogens and AG-GMO products assets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets, net of transaction fees		$ 12,075
Gain on sale of assets, net of transaction fees		$ 9,882
Food pathogens and AG-GMO products assets | Additional consideration if it is able to meet certain conditions as provided for in the Asset Purchase Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets, net of transaction fees						300
Additional consideration receivable, maximum						$ 600

PROPERTY AND EQUIPMENT (Detail

PROPERTY AND EQUIPMENT (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2013USD ($)
Property, Plant and Equipment
Depreciation expense included in discontinued operations	$ 563

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Expenses
Compensation	$ 72	$ 112
Professional fees	83	122
Other	196	252
Total accrued expenses	$ 351	$ 486

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 24	$ 5	$ 1,466
Stock options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 13	$ 5	611
Employee stock purchase plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense			1
Restricted stock awards and restricted stock units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 11		$ 854

SHARE-BASED COMPENSATION (Det34

SHARE-BASED COMPENSATION (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Shares
Beginning Balance	974,570	1,479,494	2,170,043
Granted	60,000	23,076	556,200
Cancelled / Forfeited	(350,000)	(528,000)	(1,246,749)
Ending Balance	684,570	974,570	1,479,494
Vested and exercisable at December 31, 2015	654,570
Weighted Average Remaining Contractual term
Outstanding at end of period	4 years 2 months 12 days
Vested and exercisable at December 31, 2013	4 years 1 month 6 days
Balance. January 1, 2013
Number of Shares
Price range, lower limit			$ 1.49
Price range, upper limit			4.65
Granted
Number of Shares
Price range, lower limit	$ 1.24	$ 1.30	1.19
Price range, upper limit	1.24	1.30	1.50
Cancelled / forfeited
Number of Shares
Price range, lower limit	1.25	1.50	1.19
Price range, upper limit	1.50	4.60	4.65
Balance, December 31, 2013
Number of Shares
Price range, lower limit			1.25
Price range, upper limit			$ 4.60
Balance, December 31, 2014
Number of Shares
Price range, lower limit		1.25
Price range, upper limit		$ 3.74
Balance, December 31, 2015
Number of Shares
Price range, lower limit	1.24
Price range, upper limit	3.74
Vested and exercisable at December 31,2015
Number of Shares
Price range, lower limit	1.24
Price range, upper limit	$ 3.74

SHARE-BASED COMPENSATION (Det35

SHARE-BASED COMPENSATION (Details 2)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Range of Exercise Prices $ 1.24 - $ 1.85
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Limit	$ 1.24
Upper Limit	$ 1.85
Options Outstanding, Number of Shares | shares	477,528
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price	$ 1.51
Options Exercisable, Number of Shares | shares	447,528
Options Exercisable, Wtd. Average Exercise Price	$ 1.53
Range of Exercise Prices $ 2.00 - $ 2.25
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Limit	2
Upper Limit	$ 2.25
Options Outstanding, Number of Shares | shares	175,000
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 2.13
Options Exercisable, Number of Shares | shares	175,000
Options Exercisable, Wtd. Average Exercise Price	$ 2.13
Range of Exercise Prices $ 3.69 - $ 3.74
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Limit	3.69
Upper Limit	$ 3.74
Options Outstanding, Number of Shares | shares	32,042
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 3.72
Options Exercisable, Number of Shares | shares	32,042
Options Exercisable, Wtd. Average Exercise Price	$ 3.72
Range of Exercise Prices $ 1.24 - $ 3.74
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower Limit	1.24
Upper Limit	$ 3.74
Options Outstanding, Number of Shares | shares	684,570
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 1.77
Options Exercisable, Number of Shares | shares	654,570
Options Exercisable, Wtd. Average Exercise Price	$ 1.80

SHARE-BASED COMPENSATION (Det36

SHARE-BASED COMPENSATION (Details 3) - Restricted stock awards - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Shares
Beginning Balance			445,000
Granted	15,000		225,000
Vested	(7,500)		(620,000)
Cancelled / forfeited			(50,000)
Ending Balance	7,500
Weighted Average Grant Date Fair Value
Beginning Balance	$ 0	$ 0	$ 1.60
Granted	1.13	0	1.58
Vested	$ 1.13	0	1.60
Cancelled / forfeited		0	1.59
Ending Balance	$ 1.13	$ 0	$ 0

SHARE-BASED COMPENSATION (Det37

SHARE-BASED COMPENSATION (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit related to share-based compensation expense			$ 0	$ 0	$ 0
Stock-based compensation expense			$ 24	5	28
Proceeds from Employee Restricted Share Purchase					$ 4
Vested and exercisable at December 31, 2015			654,570
Unrecognized compensation expense related to outstanding non-performance based stock options			$ 5
Asset Sale
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to acceleration of vesting to be expensed		$ 1,169
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price as a percentage of fair market value at date of grant			100.00%
Restricted stock granted, vest periods			2 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted, vest periods			5 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted during the period						410,000
Forfeited during the period						200,000
Vested during the period					210,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to acquire shares of common stock					350,000
Stock Options | Asset Sale
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to acceleration of vesting to be expensed		431
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 11	$ 0	$ 854
Unvested restricted stock (in shares)			7,500			445,000
Unrecognized compensation expense related to outstanding non-performance based stock options			$ 6
Granted during the period			15,000		225,000
Forfeited during the period					50,000
Vested during the period			7,500		620,000
Common shares issued			2,500
Restricted stock awards | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares issued	5,000
Restricted stock awards | Asset Sale
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to acceleration of vesting to be expensed		$ 738
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of issuable common stock under the plan			661,157
Employee Stock Purchase Plan, purchase price as percentage of fair market value of a share of common stock on first or last day of quarter			90.00%
2000 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of issuable common stock under the plan			8,000,000
2000 Plan | On a 100% basis matching contributions | stockholders owning more than 10% of common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price as a percentage of fair market value at date of grant			110.00%
2000 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and exercisable at December 31, 2015			654,570
Options weighted average exercise price			$ 1.80
Options shares available for future grant			3,921,011
Weighted average fair value at date of grant for options granted			$ 0.23	$ 0.40	$ 0.31
Share based compensation weighted-average assumptions, dividend yield			0.00%
Share based compensation weighted-average assumptions, expected volatility			26.00%	38.00%	38.00%
Share based compensation weighted-average assumptions, risk free interest rate			1.71%	1.71%	1.05%
Share based compensation weighted-average assumptions, expected life			4 years 3 months	5 years 6 months	5 years
2000 Plan | Nonqualified Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price as a percentage of fair market value at date of grant			85.00%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Commitments and Contingencies Disclosure [Line Items]
Rent expense	$ 28	$ 28	$ 28
United Kingdom
Commitments and Contingencies Disclosure [Line Items]
Number of real property leases	1
Lease terms expiration date	November 2,016
Annual principal rent payments	$ 150

RETIREMENT SAVINGS PLAN (Detail

RETIREMENT SAVINGS PLAN (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2013
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Recognized expenses under retirement savings plan		$ 124
On a 100% basis matching contributions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company matching contribution percentage	100.00%
Company maximum gross wages contribution percentage	1.00%
On a 50% basis matching contributions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company matching contribution percentage	50.00%
Company maximum gross wages contribution percentage	5.00%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Income Loss From Continuing Operations [Line Items]
Loss from continuing operations before taxes	$ (1,216)	$ (1,240)	$ (1,851)
United States
Schedule Of Income Loss From Continuing Operations [Line Items]
Loss from continuing operations before taxes	$ (1,216)	$ (1,240)	$ (1,851)
Rest of the world
Schedule Of Income Loss From Continuing Operations [Line Items]
Loss from continuing operations before taxes

INCOME TAXES (Details 1)

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Statutory tax rate	34.00%	34.00%	34.00%
Stock compensation expense			(34.80%)
Subpart F income			(9.80%)
Research and development credits			(0.20%)
Total	0.00%	0.00%	0.00%
Federal
Income Taxes [Line Items]
Valuation allowance	(34.00%)	(27.10%)	20.90%
Discontinued Operations
Income Taxes [Line Items]
Valuation allowance		(6.90%)	(10.10%)

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Tax
Net operating loss carryforwards	$ 8,281	$ 7,513
Credit carryforwards	1,297	1,310
Non-deductible reserves	326	574
Total deferred tax assets	9,904	9,397
Valuation Allowance	$ (9,904)	$ (9,397)
Net deferred tax assets

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - Internal Revenue Service (IRS) $ in Thousands	Dec. 31, 2015USD ($)
Operating Loss Carryforwards [Line Items]
Net Operating Loss	$ 20,098
2,022
Operating Loss Carryforwards [Line Items]
Net Operating Loss	1,674
2,024
Operating Loss Carryforwards [Line Items]
Net Operating Loss	1,876
2,025
Operating Loss Carryforwards [Line Items]
Net Operating Loss	3
2,026
Operating Loss Carryforwards [Line Items]
Net Operating Loss	1
2,027
Operating Loss Carryforwards [Line Items]
Net Operating Loss	1
2,028
Operating Loss Carryforwards [Line Items]
Net Operating Loss	3,492
2,029
Operating Loss Carryforwards [Line Items]
Net Operating Loss	2,501
2,030
Operating Loss Carryforwards [Line Items]
Net Operating Loss	1,281
2,031
Operating Loss Carryforwards [Line Items]
Net Operating Loss	391
2,033
Operating Loss Carryforwards [Line Items]
Net Operating Loss	6,625
2,034
Operating Loss Carryforwards [Line Items]
Net Operating Loss	452
2,035
Operating Loss Carryforwards [Line Items]
Net Operating Loss	$ 1,801

INCOME TAXES (Details 4)

INCOME TAXES (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Gross unrecognized tax benefits as of January 1	$ 628	$ 619	$ 590
Increases from positions taken in prior periods			2
Increases from positions taken in current period		$ 9	27
Gross unrecognized tax benefits as of December 31	$ 628	$ 628	$ 619

INCOME TAXES (Details Textuals)

INCOME TAXES (Details Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Income tax expense (benefit)
Increase in valuation allowance for deferred tax assets	$ 507
Net operating losses which, if realized, would be accounted for as additional paid in capital	668
Net operating losses related to unrecognized tax benefits	1,257
Unrecognized tax benefits	628	$ 628	$ 619	$ 590
Net operating loss and tax credit carryforwards	622
Unrecognized tax benefits interest or penalty accrued	0
Balance remaining unrecognized tax benefit included de minimis interest and penalty	$ 6
Minimum
Income Taxes [Line Items]
Operating loss carryforwards, expiration year	2,020
Maximum
Income Taxes [Line Items]
Operating loss carryforwards, expiration year	2,032
Valuation Allowance, Operating Loss Carryforwards
Income Taxes [Line Items]
Increase in valuation allowance for deferred tax assets	$ 412
Valuation Allowance, Deferred Tax Assets
Income Taxes [Line Items]
Increase in valuation allowance for deferred tax assets	95
Internal Revenue Service (IRS)
Income Taxes [Line Items]
Federal research and experimentation credit carryforwards	1,068
Federal research and experimentation credit carryforwards related to unrecognized tax benefits	119
Internal Revenue Service (IRS) | Indefinite lives
Income Taxes [Line Items]
Federal alternative minimum tax credit carryforwards	$ 10

QUARTERLY FINANCIAL DATA (Detai

QUARTERLY FINANCIAL DATA (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information
Loss from continuing operations	$ (406)	$ (268)	$ (291)	$ (251)	$ (296)	$ (261)	$ (343)	$ (340)	$ (1,216)	$ (1,240)	$ (1,851)
Income from discontinued operations							250			250	580
Net income (loss)	$ (406)	$ (268)	$ (291)	$ (251)	$ (296)	$ (261)	$ (93)	$ (340)	$ (1,216)	$ (990)	$ (1,271)
Basic and diluted loss per share from continuing operations (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.06)	$ (0.06)	$ (0.09)
Basic and diluted income per share from discontinued operations							$ 0.01			0.01
Basic and diluted net loss per share (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.01)		$ (0.02)	$ (0.06)	$ (0.05)	$ (0.06)

SUBSEQUENT EVENT (Detail Textua

SUBSEQUENT EVENT (Detail Textual) - SUBSEQUENT EVENT - B. Riley & Co., LLC $ in Thousands	1 Months Ended
	Feb. 29, 2016USD ($)shares
Subsequent Event [Line Items]
Number of shares sold by related party	742,344
Shares purchase in transaction	3,504,172
Amount paid to company for disgorgement of profits | $	$ 133